Product Data Sheet

Product Name: SIRT2-IN-9
Cat. No.: GC66026

Chemical Properties

Cas. No.	522650-91-5		
Formula	$C_{21}H_{22}N_6OS_2$	M.Wt	438.57
Solubility	DMSO : 4.46 mg/mL (10.17 mM; ultrasonic and warming and heat to 70°C)	Storage	4°C, protect from light
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			



Background

SIRT2-IN-9 (compound 12) is a selective inhibitor of **SRIT2** with an **IC_{50}** value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1].

SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC_{50} value of 1.3 μM, and

Product Data Sheet

inhibits SRIT1 and SRIT3 with IC_{50}s ??300 μM[1].

SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells [1].

SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein [1].

Cell Proliferation Assay[1]

Cell Line:	MCF-7 breast cancer cell line
Concentration:	0-50 μM
Incubation Time:	72 hours
Result:	Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells.

Western Blot Analysis[1]

Cell Line:	MCF-7 breast cancer cell line
Concentration:	6.25, 12.5, 25 and 50 μM
Incubation Time:	6 hours
Result:	Dose-dependently increased acetylation of α-tubulin protein.

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA